The U.S. Food and Drug Administration has approved FILSPARI (sparsentan) from Travere Therapeutics Inc. (NASDAQ: TVTX) to reduce proteinuria in ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

FDA